Special Issue

Immune Responses to Papillomavirus Infections: 2nd Edition

Message from the Guest Editor

Human papillomavirus (HPV) infection is the most common sexually transmitted disease that causes approximately 5% of human cancers. Current prophylactic vaccines are effective at preventing HPV infections but provide no therapeutic effect on preexisting HPV infections. Intriguingly, most HPV (about 90%) infections are cleared by hosts within 1–2 years after exposure. Understanding host control of HPV infections will potentially shed light on the development of novel therapy for HPV-associated diseases and cancers. In view of the success of the first volume (https://www.mdpi.com/journal/viruses/special_issues/2) 2667S4AC9) and the continued interest it generated, we plan to reopen this second volume. The current issue still covers research relating to how the immune system effectively clears papillomavirus infections, and what immune responses are key factors in this optimum outcome. We would like to invite you to share your recent findings or perspectives on host immunity to papillomavirus, including but not limited to innate and adaptive immune responses in preclinical models and human studies.

Guest Editor

Dr. Jiafen Hu Department of Pathology, Pennsylvania State University College of Medicine, Hershey, PA 17033, USA

Deadline for manuscript submissions

30 June 2026



Viruses

an Open Access Journal by MDPI

Impact Factor 3.5 CiteScore 7.7 Indexed in PubMed



mdpi.com/si/216321

Viruses Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 viruses@mdpi.com

mdpi.com/journal/

viruses





Viruses

an Open Access Journal by MDPI

Impact Factor 3.5 CiteScore 7.7 Indexed in PubMed



viruses



About the Journal

Message from the Editor-in-Chief

Viruses (ISSN 1999-4915) is an open access journal which provides an advanced forum for studies of viruses. It publishes reviews, regular research papers, communications, conference reports and short notes. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced. We also encourage the publication of timely reviews and commentaries on topics of interest to the virology community and feature highlights from the virology literature in the 'News and Views' section.

Electronic files or software regarding the full details of the calculation and experimental procedure, if unable to be published in a normal way, can be deposited as supplementary material.

Editor-in-Chief

Dr. Eric O. Freed HIV Dynamics and Replication Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.6 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2025).